NCT04524221View on ClinicalTrials.gov

PTG-100 for Patients With Celiac Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 26, 2021

Primary Completion Date

April 3, 2022

Study Completion Date

April 3, 2022

Conditions
Celiac Disease
Interventions
DRUG

PTG-100

PTG-100, 600mg taken twice daily in capsule form for 42 days

DRUG

Placebo

Placebo taken twice daily in capsule form for 42 days

Trial Locations (1)

94063

Stanford University, Redwood City

All Listed Sponsors
collaborator

Protagonist Therapeutics, Inc.

INDUSTRY

lead

Nielsen Fernandez-Becker

OTHER

NCT04524221 - PTG-100 for Patients With Celiac Disease | Biotech Hunter | Biotech Hunter